Theilhaber, Joachim http://orcid.org/0000-0001-5071-1183
Chiron, Marielle
Dreymann, Jennifer
Bergstrom, Donald
Pollard, Jack
Article History
Received: 4 September 2019
Accepted: 13 July 2020
First Online: 25 July 2020
Ethics approval and consent to participate
: The AFLAME clinical trial was sponsored by Sanofi and Regeneron, coordinated by Sanofi Clinical Sciences & Operations, and conducted in accordance with all procedural and ethical regulations as determined by the governmental Institutional Review Boards (IRBs) of the participating countries (China, Singapore, Japan and Taiwan). The TNBC clinical trial was sponsored by Sanofi and the BiPar Pharmaceuticals Corporation, and conducted in accordance with all procedural and ethical regulations as determined by the governmental and local IRBs of the participating countries. A complete list of all Institutional Review Boards and Ethics Committees for both the AFLAME and TNBC studies is provided in Additional file InternalRef removed.
: Not applicable.
: At the time of the AFLAME and Iniparib clinical trials, the authors were all employees of Sanofi Oncology. Sanofi is maker of the drug aflibercept and was sponsor of AFLAME. JT, MC and JP are currently Sanofi employees and detain Sanofi stock. No role whatsoever was played by Relay Therapeutics in either of these trials or in the elaboration of the compounds used.